A Study of ZW251 in Participants With Advanced Solid Tumors

StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment increased: 100 → 140 participants
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 1 of 11 entries
    • Site details revised at 1 of 25 sites
  2. Study sites: 23 to 25v7
  3. Primary endpoint(s) modifiedv6 Show 4 more changesShow less
    • Trial sites expanded: 20 → 23 locations
    • Eligibility criteria expanded, about 38 words
    • Secondary endpoints: 12 to 11
    • Study description expanded, about 5 words
  4. Study sites: 10 to 20v5
  5. Study sites: 3 to 10v4
Show 2 earlier versionsHide 2 earlier versions
  1. Study sites: 1 to 3
    • Start date changed from estimate of Sep 2025 to Oct 21, 2025
    v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell non-small cell lung cancer (NSCLC), or germ cell tumors (GCT).
Trial Details
NCT Number NCT07164313
Lead Sponsor Zymeworks BC Inc.
Conditions
(from sponsor)		 Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor
Related terms Carcinoma, Hepatocellular, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Germ Cell and Embryonal, Neoplasms, Squamous Cell
Enrollment 140 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov